In multiple sclerosis (MS), MnSOD expression is upregulated following ocrelizumab treatment, particularly in CD19+ B cells, suggesting a role in the drug’s neuroprotective and anti-inflammatory effects through PKCβ modulation [224]. The gene discussed is SOD2; the disease is myeloid sarcoma.